|
 |
 |
 |
 |
Name:
Sector:
Chief Executive:
|
Dendreon
Healthcare
Mitchell H. Gold, M.D.
|
 |
Summary:
|
Developing cell-based therapies for the treatment of cancer
and chronic infectious disease.
|
 |
Stage of Initial
Investment:
|
Venture |
Liquidity:
|
IPO
(NASDAQ: DNDN)
|
 |
 |
 |
 |
|
|
 |
 |
3005 First Avenue
Seattle, WA 98121
Phone: 206.256.4545
Fax: 206.256.0571 |
 |
 |
|
|
|